



December 8th, 2020

M3, Inc.

Nippon Boehringer Ingelheim Co., Ltd.

M3 and Nippon Boehringer Ingelheim enter into a business partnership for diagnostic support utilizing Artificial Intelligence (AI) for ILDs and other lung diseases

M3, Inc. (Head office in Minato-ku, Tokyo; President Itaru Tanimura; URL <http://corporate.m3.com/>; hereinafter “M3”) and Nippon Boehringer Ingelheim Co., Ltd. (Head office in Shinagawa-ku, Tokyo; Representative Director, Chairman and President Yoshiaki Aono; URL: <https://www.boehringer-ingelheim.jp/>; hereinafter “NBI”) are pleased to announce that they have signed a Collaboration Agreement concerning diagnostic support for fibrosing interstitial lung diseases (ILDs) and other lung diseases.

M3 and NBI have decided to form a business partnership with the aim of contributing to the early detection of ILDs and other lung diseases. Taking advantage of each other’s strengths, M3 and NBI aim to provide a wide range of medical institutions with chest X-ray diagnostic imaging support services that utilize AI algorithms. With the support of NBI’s scientific knowledge in the respiratory field, M3 will continue to develop AI algorithms with a team of physicians.

ILDs are a group of different diseases in which inflammation and other conditions develop in air sacs of the lungs (interstitium). When ILDs progress, interstitium becomes progressively thickened and stiff (fibrosing), causing difficulty in gas exchange and breathing¹. Studies have shown that areas of the lung affected by fibrosis do not readily recover. There are a variety of ILDs that involve pulmonary fibrosis, but cases with poor prognosis have a higher risk of complications such as lung cancer and heart failure², or acute deterioration of conditions. Representing progressive ILDs could lead to death. Early diagnosis and early treatment are the key to slow disease progression.

Under this partnership, M3 and NBI aim to offer services to medical institutions to achieve early diagnosis of ILDs and other lung diseases, thereby improving patients’ quality of life.

About M3

M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 290,000+ members, equivalent to 90+% of physicians in Japan, and offers services such as marketing and clinical trial support towards pharmaceutical clients.

M3’s AI Lab has been involved in 45 AI development projects for diagnostic support since its establishment in April 2017, and commenced AI platform business in May 2020. Additionally, recent business expansion that encompass the wider healthcare industry has brought forth initiatives such as “7P Projects,” which aim to integrate such businesses in order to provide holistic solutions for various therapeutic areas. Furthermore, presence

outside of Japan include the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 6.0 million physicians as members across our global platforms, allowing provision of a wide range of services.

About Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

Boehringer Ingelheim is supporting people living with pulmonary fibrosis by providing the websites IPF.jp and kyohisyo.jp enabling patients to learn more about their condition and connect with resources to help them and their loved ones.

Go to the web pages below for more details.

<http://www.boehringer-ingelheim.com/>

(Boehringer Ingelheim)

<http://www.boehringer-ingelheim.jp/>

(Boehringer Ingelheim Japan)

Reference

1. <https://www.nanbyou.or.jp/entry/156>
2. Diagnosis and treatment guidelines for idiopathic interstitial pneumonia, Diffuse lung disease diagnosis and treatment guideline development committee of the Japanese Society of Respiratory Medicine Health and Labor Science Research Specific Disease Control Project Diffuse lung disease research